Johnson & Johnson (JNJ) : Oxbow Advisors reduced its stake in Johnson & Johnson by 2.64% during the most recent quarter end. The investment management company now holds a total of 37,774 shares of Johnson & Johnson which is valued at $4,680,199 after selling 1,026 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.Johnson & Johnson makes up approximately 0.66% of Oxbow Advisors’s portfolio.
Other Hedge Funds, Including , Investors Capital Advisory Services reduced its stake in JNJ by selling 2,104 shares or 5.95% in the most recent quarter. The Hedge Fund company now holds 33,242 shares of JNJ which is valued at $4,118,684. Johnson & Johnson makes up approx 0.79% of Investors Capital Advisory Services’s portfolio.St. James Investment Company boosted its stake in JNJ in the latest quarter, The investment management firm added 616 additional shares and now holds a total of 7,299 shares of Johnson & Johnson which is valued at $904,346. Johnson & Johnson makes up approx 0.11% of St. James Investment Company’s portfolio.Smith Salley Associates boosted its stake in JNJ in the latest quarter, The investment management firm added 838 additional shares and now holds a total of 52,907 shares of Johnson & Johnson which is valued at $6,625,544. Johnson & Johnson makes up approx 1.49% of Smith Salley Associates’s portfolio. Lmr Partners Llp sold out all of its stake in JNJ during the most recent quarter. The investment firm sold 5,627 shares of JNJ which is valued $704,669.Hollencrest Securities reduced its stake in JNJ by selling 2,225 shares or 17.33% in the most recent quarter. The Hedge Fund company now holds 10,613 shares of JNJ which is valued at $1,303,807. Johnson & Johnson makes up approx 0.20% of Hollencrest Securities’s portfolio.
Johnson & Johnson closed down -0.59 points or -0.47% at $123.65 with 52,32,469 shares getting traded on Monday. Post opening the session at $124, the shares hit an intraday low of $123.23 and an intraday high of $124.15 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.